Treatment with subcutaneous apomorphine will be initiated according to the usual procedures at each centre. Once the patient is included in the study, he/she will be followed for 24 months according to a schedule of visits corresponding to his/her follow-up care. The procedures outside of the patient's usual care are only more in-depth clinical assessments and examinations (interviews with a nurse, skin lesion assessment scale, quality of life scales, neurological and cognitive assessment scales). At each visit, the patient will be seen in consultation by a state-qualified nurse from the neurology department who will conduct * nursing interviews to assess tolerance and compliance with treatment. She will also look for data concerning the flow rate, the duration of the subcutaneous apomorphine pump and the injection methods (material used, rotation of injection sites, massages). * collection of adverse effects and changes in concomitant treatments. * assessment of skin complications (number, location, characteristics: size, pain, inflammation). For centres that do not have a nurse dedicated to monitoring these patients, the above procedure will be carried out by the neurologist. In all cases, the patient will receive a consultation (in the department or remotely) by the neurologist. The tests and scales performed at inclusion will be repeated at each six-monthly visit.
Study Type
OBSERVATIONAL
Enrollment
108
observationnal
CHU Amien
Amiens, France
RECRUITINGCHU Caen
Caen, France
RECRUITINGCH de Dreux
Dreux, France
RECRUITINGCHRU Lille
Lille, France
RECRUITINGHôpital St Vincent de Paul
Lille, France
RECRUITINGChu Rouen
Rouen, France
RECRUITINGClinique Saint Hilaire
Rouen, France
RECRUITINGthe occurrence of at least one painful
pain rating scale ≥ 1/10
Time frame: up to 24 weeks
the occurence of treatment discontinuation
skin nodule any size
Time frame: up to 24 weeks
Assessment of nodules
number, localisation
Time frame: at stopping apomorphine
assessment of the pain of nodules or erythema
Visual Analogue Scale from 1 to 10:
Time frame: up to 24 weeks
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale
Time frame: six-monthly visit
Hoehn and Yahr
Time frame: six-monthly visit
Parkinson's Disease Questionnaire : quality of life scale,
Time frame: six-monthly visit
Test of Montreal Cognitive Assessment
Time frame: six-monthly visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.